/PRNewswire/ Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the.
Henry Ford Hospital cardiologists are first in the U.S. to implant circulatory support device
Cardiologists at Henry Ford Hospital are first in the U.S. and second in the world to implant a circulatory support device that is being investigated in a clinical trial for patients hospitalized with acute decompensated heart failure (ADHF) and worsening kidney function, a condition known as cardiorenal syndrome.
The Aortix™ System from Procyrion, Inc. is an intra-aortic axial flow pump, which is deployed via a femoral catheter to the descending aorta. This tiny pump, thinner than the size of a #2 pencil, is designed to relieve some of the heart s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.
Credit: Procyrion, Inc.
DETROIT (June 3, 2021) - Cardiologists at Henry Ford Hospital are first in the U.S. and second in the world to implant a circulatory support device that is being investigated in a clinical trial for patients hospitalized with acute decompensated heart failure (ADHF) and worsening kidney function, a condition known as cardiorenal syndrome.
The Aortix™ System from Procyrion, Inc. is an intra-aortic axial flow pump, which is deployed via a femoral catheter to the descending aorta. This tiny pump, thinner than the size of a #2 pencil, is designed to relieve some of the heart s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.
Share this article
Share this article
HOUSTON, May 25, 2021 /PRNewswire/ Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today successful treatment of the first patients in the company s pilot trial to evaluate the performance of its novel Aortix™ percutaneous mechanical circulatory support (pMCS) device in patients with cardiorenal syndrome (CRS). The company began its pilot trial in Australia and recently expanded to the U.S. after receiving Investigational Device Exemption (IDE) approval in April from the U.S. Food and Drug Administration (FDA). We are thrilled to be the first center in the U.S. to treat CRS patients with the Aortix device. The procedure was performed safely and easily due to the pump s position in the aorta versus the heart, which allowed for rapid deployment of the catheter-based pump and significantly reduced the risk of stroke and damage to the heart, stated Dr. Jenni